Markedly, Rhein could reversibly bind to FTO catalytic domain and competitively prevent the recognition of m6A modification substrates or alleviated the growth of subcutaneous breast cancer in mice, while another FTO inhibitor meclofenamic acid could effectively increase mRNA methylation levels in glioblastoma stem cells (GSCs) and suppress GSC growth (33, 159). Here, FTO is linked to glioblastoma.